WESTBURY, N.Y., May 6, 2014 /PRNewswire/ -- Vasomedical, Inc.
(OTC BB: VASO) announced today that it will release its financial
results for the three months ended March 31,
2014 on Wednesday, May 14,
2014, before markets open.
The Company will host a conference call on Wednesday, May 14th at 10:00 a.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO of Vasomedical,
and Michael Beecher, Chief Financial
Officer of Vasomedical. To dial into the conference call, please
dial 1-866-393-1344 from the U.S. or 1-631- 291-4669,
internationally. All dial-in participants must use the following
code to access the call: 42076306. Please call at least five
minutes before the scheduled start time. The conference call will
also be available via webcast and can be accessed through the
Investor Relations section of Vasomedical's website,
www.vasomedical.com. Please allow extra time prior to the call to
visit the site and download any necessary software to listen to the
live broadcast.
A replay of the conference call will be available approximately
two hours after completion of the live conference call at
www.vasomedical.com. To access the dial-in replay of the call,
which will be available until June 14,
2014, please dial 1-855-859-2056 or 1-404-537-3406. All
dial-in participants must use the following code to access the
call: 42076306.
About Vasomedical
Vasomedical, Inc. is a diversified
medical technology company specializing in the manufacture and sale
of medical devices and in the domestic sale of diagnostic imaging
products. The Company's main proprietary products are
EECP® Therapy systems, the gold standard of ECP
treatment. The Company operates through three wholly owned
subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare.
VasoSolutions manages and coordinates the design, manufacture and
sales of EECP® Therapy systems, and other medical equipment
operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare
is the operating subsidiary for the exclusive sales representation
of GE Healthcare diagnostic imaging products in certain market
segments. Additional information is available on the Company's
website at www.vasomedical.com.
Investor Contacts:
Todd
Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
SOURCE Vasomedical, Inc.